324 related articles for article (PubMed ID: 34235638)
1. Gene Editing and Modulation: the Holy Grail for the Genetic Epilepsies?
Carpenter JC; Lignani G
Neurotherapeutics; 2021 Jul; 18(3):1515-1523. PubMed ID: 34235638
[TBL] [Abstract][Full Text] [Related]
2. Haploinsufficiency, Dominant Negative, and Gain-of-Function Mechanisms in Epilepsy: Matching Therapeutic Approach to the Pathophysiology.
Carvill GL; Matheny T; Hesselberth J; Demarest S
Neurotherapeutics; 2021 Jul; 18(3):1500-1514. PubMed ID: 34648141
[TBL] [Abstract][Full Text] [Related]
3. Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders.
Raikwar SP; Kikkeri NS; Sakuru R; Saeed D; Zahoor H; Premkumar K; Mentor S; Thangavel R; Dubova I; Ahmed ME; Selvakumar GP; Kempuraj D; Zaheer S; Iyer SS; Zaheer A
J Neuroimmune Pharmacol; 2019 Dec; 14(4):608-641. PubMed ID: 31011884
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas13a system: a novel approach to precision oncology.
Zhang J; You Y
Cancer Biol Med; 2020 Feb; 17(1):6-8. PubMed ID: 32296572
[No Abstract] [Full Text] [Related]
5. Enabling Precision Medicine with CRISPR-Cas Genome Editing Technology: A Translational Perspective.
Ilahibaks NF; Hulsbos MJ; Lei Z; Vader P; Sluijter JPG
Adv Exp Med Biol; 2023; 1396():315-339. PubMed ID: 36454475
[TBL] [Abstract][Full Text] [Related]
6. From molecules to medicines: the dawn of targeted therapies for genetic epilepsies.
Demarest ST; Brooks-Kayal A
Nat Rev Neurol; 2018 Dec; 14(12):735-745. PubMed ID: 30448857
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
[TBL] [Abstract][Full Text] [Related]
10. A new era of gene editing for the treatment of human diseases.
Kc M; Steer CJ
Swiss Med Wkly; 2019 Jan; 149():w20021. PubMed ID: 30685869
[TBL] [Abstract][Full Text] [Related]
11. [CRISPR-Cas system as molecular scissors for gene therapy].
Heinz GA; Mashreghi MF
Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
[TBL] [Abstract][Full Text] [Related]
12. A CRISPR/CAS9-based strategy targets the personalized chimeric neosequence in fusion-driven cancer genome for precision medicine.
Huang W; Zeng ZC; Wang WT; Sun YM; Chen YQ; Luo XQ; Fang K
Clin Transl Med; 2021 Mar; 11(3):e355. PubMed ID: 33783997
[No Abstract] [Full Text] [Related]
13. Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects.
Rahman MM; Tollefsbol TO
Methods; 2021 Mar; 187():77-91. PubMed ID: 32315755
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas-Mediated Base Editing: Technical Considerations and Practical Applications.
Molla KA; Yang Y
Trends Biotechnol; 2019 Oct; 37(10):1121-1142. PubMed ID: 30995964
[TBL] [Abstract][Full Text] [Related]
15. Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.
Shalaby K; Aouida M; El-Agnaf O
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027946
[TBL] [Abstract][Full Text] [Related]
16. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy.
Nelson CE; Wu Y; Gemberling MP; Oliver ML; Waller MA; Bohning JD; Robinson-Hamm JN; Bulaklak K; Castellanos Rivera RM; Collier JH; Asokan A; Gersbach CA
Nat Med; 2019 Mar; 25(3):427-432. PubMed ID: 30778238
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Genome Editing and its Potential Enhancement through CRISPR Guide RNA and Cas9 Modifications.
Batzir NA; Tovin A; Hendel A
Pediatr Endocrinol Rev; 2017 Jun; 14(4):353-363. PubMed ID: 28613045
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas System: The Current and Emerging Translational Landscape.
Bhokisham N; Laudermilch E; Traeger LL; Bonilla TD; Ruiz-Estevez M; Becker JR
Cells; 2023 Apr; 12(8):. PubMed ID: 37190012
[TBL] [Abstract][Full Text] [Related]
20. Gene editing using CRISPR-Cas9 for the treatment of lung cancer.
Castillo A
Colomb Med (Cali); 2016 Dec; 47(4):178-180. PubMed ID: 28293040
[No Abstract] [Full Text] [Related]
[Next] [New Search]
